3 research outputs found
Additional file 2: Figure S2. of Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation
List of Articles Which Underwent Full Text Screening. (DOCX 22 kb
Additional file 1: Table S1. of Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Investigator-assessed response across patient subgroups (efficacy-evaluable patients). Assessments and demographics for patients with metastatic BCC and locally advanced BCC. (DOCX 16 kb
Additional file 2: Table S2. of Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Most common TEAEs per 100 patient-years of exposure to vismodegib. TEAEs by type during vismodegib treatment for 1 year and after 12 months’ treatment. (DOCX 14 kb